Announced
Completed
Synopsis
Flagship Pioneering led a $126m Series C round in Omega Therapeutics, a development-stage biotechnology company, with participation from Invus, Fidelity Management & Research Company, BlackRock, Cowen, Point72, Logos Capital and Mirae Asset Capital. "We are grateful to our new and existing investors for the commitment to our bold vision of creating the industry's first fully programmable epigenetic medicines," Mahesh Karande, Omega Therapeutics President and CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.